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Available online 16 March 2016We report a 72-year-old man with a four-year history of dyscognitive seizures (with occasional secondary gen-
eralization) who developed isolated, nocturnal dry cough immediately after being started on PO phenytoin. The
coughwas not accompanied by any other symptom or sign as his physical examwas completely normal. Further
investigation with chest CT and spirometry was unremarkable. This symptom persisted for six months and did
not resolve until we weaned him off of phenytoin. According to the Naranjo Adverse Drug Reaction Probability
Scale, his cough was classiﬁed as being probably (score +6) related to the use of this antiepileptic drug. To our
knowledge, there has been only one study that reported phenytoin-triggered cough. It described a postoperative
patient who developed cough and bronchospasm after receiving IV phenytoin. By reporting our case and
discussing the literature on this speciﬁc topic, we have essentially two goals. First, we intend to remind clinicians
that isolated persistent cough can be an adverse reaction to phenytoin. Second, we hope to encourage further
studies that will be able to elucidate the association presented herein.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Nocturnal coughWe report a 72-year-old man, with no personal or family history of
seizures, who started having dyscognitive seizures – with occasional
secondary generalization – at the age of 68 years. Seizure onset occurred
four months after he had undergone uneventful prostatectomy for the
treatment of prostatic adenocarcinoma in situ. The dyscognitive sei-
zures were characterized by hand and mouth automatisms in associa-
tion with impairment of consciousness; each of the seizures lasted for
a few seconds only, andmost of themwere followed by postictal confu-
sion and tiredness. He also had positive hepatitis C serology, a previous
endovascular treatment of an unruptured intracranial aneurysm, chron-
ic headaches, lower extremity pain, hypertension, hypothyroidism, dys-
lipidemia, and ulcerative colitis. For the last four conditions just
mentioned, he was using losartan, levothyroxine, simvastatin, and
mesalazine — respectively. In terms of neurological investigation,
brain MRI was normal, while EEG study showed minimally reactive
slow background activity without epileptiform abnormalities. Several
antiepileptic drugs (AEDs) were tried: carbamazepine, oxcarbazepine,
valproate, topiramate, lamotrigine, and lacosamide— all of which need-
ed to be discontinued because of side effects. Seizure freedom was not
achieved until he was started on phenytoin. Initially, the phenytoin
was given at a dose of 300 mg/day. However, the dose had to be gradu-
ally decreased because of complaints of unsteadiness and poor balance.o, 300, CEP 81210-310, Curitiba,
. Nascimento),
gmail.com,
. This is an open access article underThis AED was then kept at 100 mg/day, which showed to be the maxi-
mum tolerated dose by this patient. Of note, the phenytoin prescribed
was the brand name Hidantal®, manufactured by the pharmaceutical
company Sanoﬁ-Aventis. Its excipients are comprised of starch, magne-
sium stearate, lactose monohydrate, talc, and povidone K30.
Four days after being initiated on phenytoin, however, he began to
experience isolated, nocturnal dry cough. On examination, there was
not any abnormal pulmonary ﬁndingwhatsoever. Our ﬁrst intervention
was to switch his losartan to amlodipine because the former has been
previously associated with cough [1]. Despite this change, his cough
persisted, which prompted further investigation with chest CT and spi-
rometry — both of which were normal. Six months after, still without
resolution of the cough, phenytoin was weaned off and replaced with
phenobarbital at 100 mg/day. Within the following day, the patient's
chronic cough was completely resolved. Importantly, he was not
rechallenged with phenytoin as per his desire. Presently, at 3-month
follow-up, our patient remains cough-free.
Phenytoin-induced respiratory involvement can be essentially di-
vided into two groups: (1) drug-induced interstitial pneumonitis (as
part of a generalized hypersensitivity reaction) and (2) isolated cough
and/or bronchospasm.While the former has been consistently reported
[2], rarely has phenytoin been linked to isolated cough and/or broncho-
spasm. In fact, to our knowledge, there has been only one study that de-
scribed phenytoin-induced isolated cough and bronchospasm. This
study reported a postoperative neurosurgical patient who developed
cough in association with bronchospasm immediately after rapid IV in-
fusion of phenytoin. The authors ruled out anaphylaxis as a cause of the
event based on the absence of any hemodynamic change as well as thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Reported patient's isolated chronic, nocturnal dry cough while on PO phenytoin (100 mg/day) as assessed by the Naranjo Adverse Drug Reaction Probability Scale.
Modiﬁed from Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug; 30(2):239–245.
Question Yes No Unknown Patient's score
Are there any previous conclusive reports of this reaction? +1 0 0 +1
Did the adverse event appear after the suspected drug was given? +2 −1 0 +2
Did the adverse reaction improve when the drug was discontinued or a speciﬁc antagonist was given? +1 0 0 +1
Did the adverse reaction appear when the drug was readministered? +2 −1 0 0
Are there alternative causes that could have caused the reaction? −1 +2 0 +2
Did the reaction reappear when a placebo was given? −1 +1 0 0
Was the drug detected in any body ﬂuid in toxic concentrations? +1 0 0 0
Was the reaction more severe when the dose was increased or less severe when the dose was decreased? +1 0 0 0
Did the patient have a similar reaction to the same or similar drugs in any previous exposure? +1 0 0 0
Was the adverse event conﬁrmed by any objective evidence? +1 0 0 0
Patient's total score +6
Scoring algorithm: N9 = deﬁnite ADR, 5–8 = probable ADR, 1–4 = possible ADR, 0 = doubtful ADR. ADR, adverse drug reaction.
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they postulated that this patient's cough and bronchospasm were gen-
erated by a phenytoin-triggered central sympathetic inhibition with
vagal predominance [3].
Regarding our patient, we believe that his chronic, isolated cough
was secondary to the phenytoin usemainly based on the temporal rela-
tionship between drug exposure and symptom onset as well as its com-
plete resolution immediately after drug discontinuation. Moreover, the
absence of other potential causes, as well as the previous published re-
port describing similar reaction, further supports the abovementioned
hypothesis. An alternative hypothesis would be that our patient's
cough was, in fact, periictal [4,5]. This is highly unlikely mainly because
(i) our patient's seizures (including ictal and postictal periods) were
never accompanied by cough or any other vegetative symptom, and
(ii) each of his bouts of cough lasted approximately an hour, which is
not consistent with periictal cough—which occurs, by deﬁnition, some-
time between the beginning of a seizure and a fewminutes after it ends
[4,5].
Finally, it should be noted that none of the drug excipients (which
were described above) have ever been associated with pulmonary ad-
verse effects. By estimating the probability that phenytoin caused the
reported patient's chronic cough through the scoring system proposed
by Naranjo et al. [6], we obtain a total score of +6 (Table 1). Scores
from +5 to +8 indicate that the adverse drug reaction is probable.
In summary, we report a patient with epilepsy who developed iso-
lated chronic, nocturnal dry coughwhile on therapywith PO phenytoin.
Based on the Naranjo Adverse Drug Reaction Probability Scale [6], we
can deﬁne this symptom as probably generated by the phenytoin use.
In light of the data presented herein, we conclude that, irrespective of
the drug formulation and vehicle, cough – whether in association or
not with bronchospasm – appears to be an uncommon but speciﬁc
phenytoin-related side effect. Therefore, clinicians should be familiar
with this knowledge when facing patients on phenytoin who develop
cough, with or without bronchospasm, of unclear etiology. Lastly, we
hope to encourage further studies thatwill be able to elucidate the asso-
ciation presented in this report.
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